Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 1/2 9Phase 2 7Phase 3 5

Status

Completed 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5

Conditions

Leukemia, Myeloid, Acute 5Leukemia 3

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × quizartinib × Clear all
NCT06578247 2026-04-30

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting
700 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT07478991 2026-03-18

VENP-A-QUI

PETHEMA Foundation

Phase 3 Not yet recruiting
376 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02668653 2024-08-06

QuANTUM-First

Daiichi Sankyo

Phase 3 Completed
539 enrolled 20 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT04676243 2022-05-25

Q-SOC

University Hospital Heidelberg

Phase 3 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02039726 2021-02-24

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Daiichi Sankyo

Phase 3 Completed
367 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡